Fairvalue-Calculator Fairvalue-Calculator

PharmaResources (Shanghai) Co (301230) Fair Value & Analysis

Healthcare · CN · Market cap 4.7B CNY

Price¥35.17
Fair Value¥5.41
Upside-84.6%
Quality95/100
Evidence: High Range ¥4.05 – ¥6.76

Analysis

PharmaResources (Shanghai) Co (301230) currently trades at ¥35.17, while our model-based Fair Value estimate is ¥5.41 — implying the stock looks roughly 84.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

PharmaResources (Shanghai) Co., Ltd. engages in new drug research, development, and commercial production in China. It offers small molecule drug CRO, CDMO, and CMO. The company also involved in drug discovery, research, and development of pharmaceutical processes; and customized and commercial production of APIs, and key intermediates. It serves global pharmaceutical and biotechnology companies. PharmaResources (Shanghai) Co., Ltd. was founded in 2007 and is based in Shanghai, China

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Alnylam Pharmaceuticals, Inc (ALNY) -82% Samsung Biologics Co (207940) +9%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.